Here are the biggest stories to feature on BioPharma-Reporter during April:
The difficulties in the manufacture of CAR-T treatments have become increasingly understood as the breakthrough technology has been commercialised, but Kite’s head of medical affairs told us its process is nearly flawless.
The pace at which the Chinese biotech ecosystem is growing has been missed by Europeans, suggested one executive at BIO-Europe Spring.
The Danish company invested in the rebuild of its existing facilities and plans to add further production equipment at its site in Kalundborg.
The first-ever Soliris biosimilar approved in Russia, after it was produced through Selexis’ SureTechnology platform and cell line.
Teva’s anti-CGRP migraine drug lines up next to its competitors, after the European Commission granted it marketing authorization.
BeiGene partnered with BioAtla to develop and commercialise the latter’s CTLA-4 antibody, which will be explored for use alongside a PD-1 antibody.
Biogen halts all clinical trial activity on its Alzheimer’s drug, aducanumab, after its failure in Phase III trials.
US FDA granted orphan drug designation for Hyleukin-7, an immuno-oncology agent that boosts T cell production and functionality, for the treatment of ICL.
Despite increased competition from biosimilars in Europe, Roche announced sales of its pharmaceutical divisions are up by 10%.
Novartis investigates the death of an infant in a gene therapy clinical trial to determine whether it was related to the treatment but does not anticipate an impact on FDA approval.